Petros Pharmaceuticals (PTPI) 10-Q2024 Q1 Quarterly report

Filed: 15 May 24, 5:00pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Bad

New words: accessing, accrual, accurate, advisory, analyze, announced, Announcement, app, appeal, Article, attract, bid, broker, comply, confidence, constitute, convenient, CoreIR, CorProminence, coupled, CRO, delist, delisted, delisting, difficulty, disaggregated, disaggregation, District, emphasizing, February, fewer, flagship, free, goal, halted, human, impose, indefinitely, innovator, investor, jurisdiction, Justice, largely, leading, mezzanine, multiple, notification, Ontario, OTCQB, penny, Pink, platform, promulgated, proportion, proven, publicly, regain, rendered, request, solicitation, successor, Superior, Switch, task, thereunder, transparency, type, unexercised, unlisted, unrecognized, upcoming, web

Removed: acute, advance, anniversary, anticipate, assure, Audit, August, authorized, awarded, basic, bearing, begin, calculating, canceled, cancellation, candidate, categorized, charge, codified, collaborative, collectability, commenced, commercialize, Commission, Committee, concession, consummated, continually, curvature, decline, degree, deposited, discretionary, disease, dissolution, distributed, dividing, earnout, employee, exceed, existed, expenditure, explored, facility, fixed, focused, footnote, formulation, fully, funding, global, head, headcount, Hybrid, identifying, impaired, improvement, Juggernaut, June, King, lease, lessor, litigation, LLP, making, measuring, necessarily, nonqualified, office, omitted, optimistic, organized, passage, patented, payroll, Peyronie, pharmacovigilance, phase, precision, prescribed, pursue, ranging, realizable, realization, recent, refer, register, renegotiating, reviewed, RSU, seek, selecting, space, sponsored, sublease, subsequently, successful, Tania, thereto, topical, turnover, uncertain, uncertainty, variety, vest, vested, weighted

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

PTPI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATION PURSUANT TO SECTION 906

OF THE SARBANES–OXLEY ACT OF 2002

In connection with the Quarterly Report of Petros Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


	Petros Pharmaceuticals, Inc.

Date: May 15, 2024	By:	/s/ Fady Boctor
		Fady Boctor
		Chief Commercial Officer and Principal Executive Officer

Date: May 15, 2024	By:	/s/ Mitchell Arnold
		Mitchell Arnold
		Vice President of Finance and Principal Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.